Money Magnet Immunocore kicks off Trial for Eye Melanoma
Immunocore (UK) has enrolled its first patient for a phase I trial that will test…
Immunocore (UK) has enrolled its first patient for a phase I trial that will test…
Unicorns are private fast-growing companies valued more than a billion euro/dollars. This club is getting…
Immunocore in Oxford (UK) has been Granted Orphan Drug Designation for a Phase I Super rare Eye…
Looking forward to 2016, I wondered which Biotechs I would watch closely. Here's my list…
2015 was a crazy year for the Biotech industry, probably the craziest since the birth…
Last Thursday at Genesis in London, I had the chance to meet with Eva-Lotta Allan, CBO…
Which part of our body do European biotechs prefer to target? And how diversified are…
Update 22/10/2015: I added Galapagos from Belgium and Basilea from Switzerland, they deserved it ...…
Cash is floating into Biotech like never before, in the US as well as in…
Adaptimmune Therapeutics, an oxford-based company focusing on the use of T-cell therapies to treat cancer,…
Immunocore Limited, just announced that it has secured a £205 million financing (€293 m) from private…
Eli Lilly expands its portfolio in immune-oncology therapies. This time, Immunocore's lead T cell receptor-based…